<DOC>
	<DOCNO>NCT01204593</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy association Lantus ( once-a-day , od ) Apidra ( thrice-a-day , tid ) term change HbA1c baseline end study ( week 24 ) , patient Type 1 Diabetes Mellitus ( T1DM ) . Secondary Objectives : To evaluate : - The change hemoglobin A1c ( HbA1c ) baseline week 12 - The percentage patient HbA1c &lt; 7 % week 12 week 24 - The FBG 7-point self monitoring blood glucose ( SMBG ) baseline , week 12 week 24 - The daily dose insulin glulisine insulin glargine baseline , week 12 week 24 - The incidence symptomatic hypoglycemia - Adverse event</brief_summary>
	<brief_title>baSal BoluS Therapy patIenTs With TypE 1 Diabetes Mellitus</brief_title>
	<detailed_description>After two-week run-in period patient enter six-month treatment period . Estimated study duration per patient : 26 week ( include 2-week run-in period ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : 1 . Known Type 1 diabetic patient ( male female ) treat type insulin regimen , except : continuous subcutaneous insulin infusion ( CSII , pump ) , patient already treat insulin glargine 2 . Age : 1860 year inclusive 3 . HbA1c : 8 % 10 % assess past 6 month 4 . At least 1 year continuous insulin treatment 5 . Willingness accept , ability follow : basal bolus regimen ( glargine x1 glulisine x3 per day ) , selfmonitoring blood glucose ( SMBG ) fix meal plan , CHO count 6 . Signed informed consent obtain prior study procedure Criteria entry treatment period : 1 . HbA1c 810 % assess week 2 week 0 2 . Serum creatinine ≤135 micromol/L men ≤110 micromol/L woman 3 . Alanine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) low equal three time upper limit normal 4 . Pregnancy test negative woman childbearing potential Exclusion criterion : 1 . History hypersensitivity insulin glargine and/or insulin glulisine 2 . Pregnant , breastfeed woman childbearing potential use efficient contraception 3 . Brittle diabetes 4 . Known impaired renal function define serum creatinine &gt; 135 micromol/L men &gt; 110 micromol/L woman study entry 5 . Known impaired hepatic function define Alanine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) great three time upper limit normal study entry 6 . Diabetes ketoacidosis 7 . History drug alcohol abuse 8 . Psychiatric mental disease 9 . Inclusion another study past 6 month previous inclusion study 10 . Patient unable unwilling manage properly basal bolus regimen The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>